Allison Brashear, M.D.Wake Forest School of Medicine

Doctor Rating

No Rating Available
Why No Ratings?

Allison Brashear, M.D.


Clinical Interests

Movement Disorders, Neuromuscular Diseases, Botulinum Toxin

Contact Information

Request An Appointment

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-716-4101
Department: 336-716-4101

Insurance Accepted »

Media Medical Expert »

Related Links

Education & Training

  • B.A., Depauw University, 1983
  • M.D., Indiana University School of Medicine, 1987
  • Internship, Medicine, Indiana Univ Med Ctr & Hosps, 1988
  • Residency, Neurology, Indiana Univ Med Ctr & Hosps, 1991

Board Certifications

  • American Board of Psychiatry and Neurology, Neurology


  • American Academy Of Neurology

NPI Number

  • 1881673713
Allison Brashear, M.D.

Doctor Rating

No Rating Available
Why No Ratings?

Allison Brashear, M.D.

Chair, Neurology
Professor, Neurology
Office of Women in Medicine and Science
Gerontology and Geriatric Medicine

Research Interests

Sodium-Potassium-Exchanging ATPase; Dystonic Disorders; Dystonia; Muscle Spasticity; Botulinum Toxins
More »

Contact Information

Request An Appointment

Academic: 336-716-3545 | Department: 336-716-4101

Media Medical Expert »

Related Links

Recent Publications

ATP1A3 mutation in adult rapid-onset ataxia. Sweadner KJ, Toro C, Whitlow CT, Snively BM, Cook JF, Ozelius LJ, Markello TC, Brashear A.. PLoS One. 2016;11(3):e0151429.

Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. Paciorkowski AR, McDaniel SS, Jansen LA, Tully H, Tuttle E, Ghoneim DH, Tupal S, Gunter SA, Vasta V, Zhang Q, Tran T, Liu YB, Ozelius LJ, Brashear A, Sweadner KJ, Dobyns WB, Hahn S.. Epilepsia. 2015;56(3):422-430.

Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P.. Lancet Neurol. 2015;14(10):992-1001.

A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin beta1 subunit, Lamb1. Liu YB, Tewari A, Salameh J, Arystarkhova E, Hampton TG, Brashear A, Ozelius LJ, Khodakhah K, Sweadner KJ.. Elife. 2015;4():e11102.

ATP1A3 mutations: what is the phenotype? [editorial]. Brashear A, Ozelius LJ, Sweadner KJ.. Neurology. 2014;82(6):468-469.

Cognitive impairment in rapid-onset dystonia-parkinsonism. Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A.. Mov Disord. 2014;29(Suppl 3):344-350.

Distinct neurological disorders with ATP1A3 mutations. Heinzen EL, Arzimanoglou A, Brashear A, Clapcote SJ, Gurrieri F, Goldstein DB, Johannesson SH, Mikati MA, Neville B, Nicole S, Ozelius LJ, Poulsen H, Schyns T, Sweadner KJ, van den Maagdenberg A, Vilsen B.. Lancet Neurol. 2014;13(5):503-514.

Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Saunders-Pullman R, Fuchs T, San Luciano M, Raymond D, Brashear A, Ortega R, Deik A, Ozelius LJ, Bressman SB.. Mov Disord. 2014;29(6):812-818.

Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B.. Acta Neuropathol. 2014;128(1):81-98.

Rapid-onset dystonia-Parkinsonism presenting as tremor-dominant Parkinson's disease (PO4.161) [abstract]. Tate J, Brashear A, Whitlow C, Snively B, Ozelius L, Sweadner K, Stacy M, Haq I.. Neurology. 2013;80(1 Meeting Abstracts):P04.

Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ.. Eur J Neurol. 2013;20(5):773-780.

Commentary. Brashear A.. Mov Disord. 2013;28(14):1939.

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin) in cervical dystonia. Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL.. J Neural Transm. 2013;120(12):1699-1707.

Coding for the use of botulinum toxin for movement disorders. Brashear A, Bushong L.. Continuum (Minneapolis, Minn.). 2013;19(5):1406-1415.

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin) injections in blepharospasm. Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH, Brashear A.. J Neural Transm. 2013;120(9):1345-1353.

Treatment of cervical dystonia. Brashear A.. Expert Opin Orphan Drugs. 2013;1(8):599-606.

Psychiatric and neurocognitive morbidity in rapid-onset dystonia Parkinsonism [abstract]. Brashear A, Cook J, Amponsah A, Hill D, Snively B, Light L, Suerken C, McCall WV, Boggs N, Stacy M, Ozelius L, Sweadner K.. Neurology. 2012;78(Suppl 1):P01.225.

Rapid-onset dystonia-Parkinsonism: more than just dystonia. Brashear A, Ozelius LJ, Sweadner KJ. In: Stacy MA, ed. Handbook of dystonia. 2nd ed. New York: Informa Healthcare;2012: 241-250.

Rapid onset dystonia-Parkinsonism associated with the I758S ATP1A3 mutation: a neuropathologic study of two affected siblings [abstract]. Ghetti B, Brashear A, Hagen M, Sweadner K.. J Neuropathol Exp Neurol. 2012;71(6):592-593.

New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A.. Parkinsonism Relat Disord. 2012;18(6):737-741.

Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, Elovic EP.. PM R. 2012;4(1):4-10.

Patient registry of outcomes in spasticity care. Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S.. Am J Phys Med Rehabil. 2012;91(9):729-746.

Psychiatric disorders in rapid-onset dystonia-parkinsonism. Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV.. Neurology. 2012;79(11):1168-1173.

Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Charles D, Brashear A, Hauser RA, Li H-I, Boo L-M, Brin MF.. Clin Neuropharmacol. 2012;35(5):208-214.

ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L.. Dev Med Child Neurol. 2012;54(11):1065-1067.

. Brashear A, Elovic E, eds. In: Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: .

Why is spasticity important?. Brashear A, Elovic E. In: Brashear A, Elovic E, eds. Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: 3-4.

Botulinum toxin in the treatment of upper limb spasticity. Brashear A. In: Brashear A, Elovic E, eds. Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: 131-140.

A diagnostic test to distinguish psychogenic dystonia from organic dystonia? [editorial]. Chen R, Brashear A.. Neurology. 2011;76(7):590-591.

Psychosis: part of the rapid-onset dystonia-Parkinsonism (RDP) phenotype? [abstract]. Brashear A, Hill DF, Boggs N, Ozelius L, Sweadner KJ, Light L, Stacy M, Snively BM, McCall WV.. Neurology. 2011;76(9 Suppl 4):A640.

Flexible dosing with incobotulinumtoxin-A (Xeomin); botulinum neurotoxin type-A, free from accessory proteins) in cervical dystonia [abstract]. Evidente VGH, Fernandez HH, LeDoux MS, Brashear A, Marx MW, Grafe SK, Comella CL.. Eur J Neurol. 2011;18(Suppl 2):511.

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S.. Parkinsonism Relat Disord. 2010;16(5):316-323.

De novo and recurrent mutations in ATP1A3 are common in rapid-onset dystonia-Parkinsonism [abstract]. Brashear A, Hill D, Snively BM, Sweadner KJ, Ozelius L.. Neurology. 2010;74(9 Suppl 2):A204.

Tizanidine improves geriatric depression scale scores in stroke and brain injury survivors with spastic hemiparesis: post-hoc analysis from a randomized, double-blind, placebo-controlled trial [abstract]. Yablon SA, Simpson D, Gracies JM, Barbano R, Brashear A.. Neurology. 2010;74(9 Suppl 2):A409-A410.

Now triggers in rapid-onset dystonia-Parkinsonism (RDP) [abstract]. Brashear A, Hill DF, Snively B, Sweadner KJ, Ozelius L.. Neurology. 2010;74(9 Suppl 2):A205.

Botulinum toxin type A: exploring new indications. Brashear A.. Drugs Today (Barc). 2010;46(9):671-682.

Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A.. J Neurol Neurosurg Psychiatry. 2009;80(4):380-385.

Spasticity. Brashear A, Lambeth K.. Curr Treat Options Neurol. 2009;11(3):153-161.

Botulinum toxin type A in the treatment of patients with cervical dystonia. Brashear A.. Biologics. 2009;3():1-7.

Rapid onset dystonia-parkinsonism: symptoms in a mouse deficient in Na,K-ATPase alpha3 [abstract]. Sacino A, Hampton TG, Lingrel JB, Brashear A, Sweadner KJ.. Mov Disord. 2009;24(Suppl 1):S112-S113.

Relationship between active function and tone in a placebo-controlled study of botulinum neurotoxin vs tizanidine in upper limb spasticity [abstract]. Gracies J-M, Yablon S, Raghavan P, Barbano R, Brashear A, Simpson D.. Arch Phys Med Rehabil. 2009;90(10):e5-e6.

Variable phenotypic expression of rapid onset dystonia parkinsonism in a newly discovered Italian family with a T613M mutation in the ATP1A3 gene [abstract]. Barbano RL, Ozelius L, Hill DF, Brashear A.. In: Abstracts of the 61st Annual Meeting of the American Academy of Neurology; 2009 April 25 - May 2; Seattle (WA). 2009;():IN2-1.003.

Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, et al.. Neurology. 2008;70(19):1699-1706.

Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C.. Arch Phys Med Rehabil. 2008;89(5):799-806.

Clinical comparisons of botulinum neurotoxin formulations. Brashear A.. Neurologist. 2008;14(5):289-298.

The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJM, Gollamudi S, Green A, Guimaraes J, Haake B, Klein C, et al.. Brain. 2007;130(Pt 3):828-835.

Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Yablon SA, Brashear A, Gordon MF, Elovic DP, Turkel CC, Daggett S, Liu J, Brin MF.. Clin Ther. 2007;29(4):683-690.

ATP1A3 mutations in rapid-onset dystonia Parkinsonism: is there more to the story? [abstract]. Brashear A, Farmer D, Wood F, Bressman SB, Dobyns WB, Ozelius LO.. Ann Neurol. 2006;60(Suppl 10):S11.

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, et al.. Neurology. 2006;67(12):2233-2235.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Neurology

Clinical Interests

Movement Disorders, Neuromuscular Diseases, Botulinum Toxin
Allison Brashear, M.D.
CP concern for questions/worries
CP efforts to include in decisions
CP explanations of prob/condition
CP spoke using clear language
Friendliness/courtesy of CP
Likelihood of recommending CP
Patients' confidence in CP
Time CP spent with patient
Wait time at clinic

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give


New Hope for the Treatment of Upper Limb Spasticity

Learn more about the symptoms of upper limb spasticity and new treatment options to help patients live better and more active lives.

Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.